GlobeNewswire

Arbitrade Completes the Purchase of the First of the Mandela Golden Hands Artifacts

Dela

A solid gold cast of Nelson Mandela's iconic raised fist sold for $2 million

NEW YORK, May 11, 2018 (GLOBE NEWSWIRE) -- Mr. Leonard Schutzman, Chairman and Chief Executive of Arbitrade, a leading coin and cryptocurrency exchange, said today the company had purchased the first item of the Nelson Mandela Golden Hands Collection. It was, he said, a solid gold cast of Mandela's fist made during his lifetime by the Harmony Gold company at his home in Johannesburg in 1964.

Arbitrade had made the purchase in accordance with the contract drawn up with the seller, Mr. Malcolm Duncan, a South African businessman in March 2018, whereby the company had agreed to buy the iconic collection that includes 3 life size impressions of Mandela's hand and 2 others of his palm and the fist.  The contract calls for Arbitrade to buy one item of the collection at quarterly intervals throughout the course of this year. East of the three remaining will cost $2.5 million.

Mr. Schutzman said, the company was pleased to have agreed to purchase the collection and was especially pleased to have acquired the 1964 cast of Mandela's fist. "It's interesting to note that when it came to casting the fist, Mandela insisted on placing his thumb next to his fingers as opposed to in front. He deemed it a less aggressive representation of his victory of apartheid. It was typical of the man."

Mr. Schutzman went on to say that apart from it being an expression of the company's deep admiration for Mandela in this, the 100th anniversary year of his birth, it was also an expression of the company's attachment to gold and all that South Africa has done through the years in supporting the gold industry.  "We intend to acquire significant amounts of gold in the coming months in order to back the coins that Arbitrade will be producing.  In acquiring the collection, we feel we had made an exceptional investment and that it is singularly appropriate that we should mark our company's interest and our intentions through the acquisition of this iconic collection."

Mr Schutzman said Arbitrade intends to show the fist in the coming weeks and even before taking possession of the entire collection, had pledged, with Mr. Duncan's support, to exhibit the artifacts in various overseas capitals. "We want as many people as possible to see the collection and to recall Mandela and his life and times," he said.

Mr. Schutzman said, it was Harmony's intention to make a full set of artifacts including the fist, to mark each of the 27 years Mandela has spent behind bars.  "Our set is dedicated to 1964 and 1990, marking the year Mandela was first incarcerated on Robben Island and the year he walked through the prison gates a free man."

He confirmed the complete set and the fist had been authenticated by Harmony Gold and is in the possession of Arbitrade together with several photographs of Mandela making the cast at his home in Johannesburg. He said these artifacts are believed to be part of an only surviving set.  All others having been destroyed by order of Nelson Mandela.

ARBITRADE, through its proprietary software and strategic partnerships, plans to be in all segments of the cryptocurrency business, including currency mining, trading (The ARBITRADE Exchange) gift cards, debit cards, money transfer and Point of Sale processing. 

Media Contact: 
Victor Webb 
Marston Webb International 
T: (212) 684-6601, C: (917) 887-0418        
e-mail: marwebint@cs.com 

Enclosures:

1 Photograph of Mandela and Harmony making the casts of Mandela's hands.
1 Letter of Authenticity covering the fist from Harmony Gold.

Photos accompanying this announcement are available at

http://resource.globenewswire.com/Resource/Download/bc285f28-3c2a-4a30-bad8-a5eef37d040f

http://resource.globenewswire.com/Resource/Download/2579ed98-e5ea-4442-acfb-76f7a84a35db




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Arbitrade via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum